Cellebrite DI Ltd (CLBT) Stock Observes 32.06% 200-Day Moving Average

In the past week, CLBT stock has gone down by -6.57%, with a monthly decline of -8.57% and a quarterly surge of 31.55%. The volatility ratio for the week is 4.34%, and the volatility levels for the last 30 days are 3.46% for Cellebrite DI Ltd The simple moving average for the past 20 days is -3.79% for CLBT’s stock, with a 32.06% simple moving average for the past 200 days.

Is It Worth Investing in Cellebrite DI Ltd (NASDAQ: CLBT) Right Now?

Additionally, the 36-month beta value for CLBT is 1.53. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for CLBT is 55.50M and currently, short sellers hold a 4.72% ratio of that float. The average trading volume of CLBT on April 04, 2024 was 978.51K shares.

CLBT) stock’s latest price update

Cellebrite DI Ltd (NASDAQ: CLBT) has seen a rise in its stock price by 2.40 in relation to its previous close of 10.83. However, the company has experienced a -6.57% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-29 that Here is how Cellebrite DI Ltd. (CLBT) and Viant Technology (DSP) have performed compared to their sector so far this year.

Analysts’ Opinion of CLBT

Many brokerage firms have already submitted their reports for CLBT stocks, with Needham repeating the rating for CLBT by listing it as a “Buy.” The predicted price for CLBT in the upcoming period, according to Needham is $13.50 based on the research report published on March 28, 2024 of the current year 2024.

BofA Securities gave a rating of “Buy” to CLBT, setting the target price at $12 in the report published on February 16th of the current year.

CLBT Trading at 3.33% from the 50-Day Moving Average

After a stumble in the market that brought CLBT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.28% of loss for the given period.

Volatility was left at 3.46%, however, over the last 30 days, the volatility rate increased by 4.34%, as shares sank -5.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.19% upper at present.

During the last 5 trading sessions, CLBT fell by -6.57%, which changed the moving average for the period of 200-days by +74.10% in comparison to the 20-day moving average, which settled at $11.49. In addition, Cellebrite DI Ltd saw 28.06% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for CLBT

Current profitability levels for the company are sitting at:

  • 0.1 for the present operating margin
  • 0.84 for the gross margin

The net margin for Cellebrite DI Ltd stands at -0.25. The total capital return value is set at 0.12. Equity return is now at value -150.08, with -17.09 for asset returns.

Based on Cellebrite DI Ltd (CLBT), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at 7.22. The debt to equity ratio resting at 0.41. The interest coverage ratio of the stock is 0.31.

Currently, EBITDA for the company is 43.29 million with net debt to EBITDA at -4.06. When we switch over and look at the enterprise to sales, we see a ratio of 6.46. The receivables turnover for the company is 4.21for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.


In conclusion, Cellebrite DI Ltd (CLBT) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts